Table 2.
Clinical and demographic characteristics of the population at baseline.
| Variable | Non-MDA patients Number = 172 |
MDA patients Number = 98 |
P |
|---|---|---|---|
| Age (years) | 52.66 ± 10.60 | 50.08 ± 8.81 | 0.042 |
| Male gender | 65 (37.8%) | 59 (60.2%) | 0.001 |
| Clinical subset | |||
| Axial + Peripheral | 63 (36.6%) | 32(32.7%) | 0.596 |
| Peripheral | 59 (34.3%) | 36 (36.7%) | 0.693 |
| Axial | 41 (23.8%) | 23 (23.5%) | 1.000 |
| Mutilans | 9(5.2%) | 7(7.1%) | 0.595 |
| MetS | 73(42.4%) | 18(18.4%) | < 0.001 |
| HS | 62(36.0%) | 14(14.3%) | < 0.001 |
| CPs | 48(27.9%) | 10(10.2%) | 0.001 |
| Disease duration (months) | 101.72 ± 74.01 | 126.93 ± 58.83 | 0.004 |
| ESR (mm/h) | 14.35 ± 11.06 | 20.16 ± 13.86 | < 0.001 |
| CRP (mg/L) | 1.66 ± 1.83 | 3.20 ± 3.28 | < 0.001 |
| SJC | 3.75 ± 4.30 | 3.80 ± 3.68 | 0.929 |
| TJC | 12.99 ± 5.62 | 10.06 ± 4.71 | < 0.001 |
| PASI | 1.49 ± 0.68 | 1.45 ± 0.76 | 0.700 |
| HAQ | 2.39 ± 1.41 | 2.61 ± 1.52 | 0.230 |
| VAS | 77.50 ± 17.30 | 75.30 ± 24.33 | 0.390 |
| Patient global VAS | 74.24 ± 21.08 | 74.28 ± 24.62 | 0.988 |
| Tender entheseal count | 11.71 ± 5.45 | 9.66 ± 5.06 | 0.003 |
| Hypercholesterolemia | 103(59.9%) | 36(36.7%) | < 0.001 |
| Hypertriglyceridemia | 60(34.9%) | 32(32.7%) | 0.790 |
| Impaired fasting glucose | 11(6.4%) | 9(9.2%) | 0.470 |
| Hypertension | 39(22.7%) | 18(18.4%) | 0.441 |
| Smoking habit | 36(20.9) | 29(29.6) | 0.138 |
| Obesity | 88(51.2%) | 23(23.5%) | < 0.001 |
Stratification according to the achieving of MDA at 12-month follow-up. CPs, presence of carotid plaques (carotid intima-media thickness > 1.3 mm); CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; HS, hepatic steatosis; MetS, metabolic syndrome; PASI, Psoriasis Area Severity Index; SJC, swollen joint count; TJC, tender joint count; VAS, Visual Analogue Scale for pain.